Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers

Kazushige Ishida, Satoshi S. Nishizuka, Takehiro Chiba, Miyuki Ikeda, Kohei Kume, Fumitaka Endo, Hirokatsu Katagiri, Teppei Matsuo, Hironobu Noda, Takeshi Iwaya, Noriyuki Yamada, Hisataka Fujiwara, Masanori Takahashi, Tetsuya Itabashi, Noriyuki Uesugi, Chihaya Maesawa, Gen Tamura, Tamotsu Sugai, Koki Otsuka, Keisuke KoedaGo Wakabayashi

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


To confirm the clinical significance of NF-κB and JNK protein expression from experimentally identified candidates for predicting prognosis for patients with 5-FU treatment, we evaluated the protein expression of surgically removed specimens. A total of 79 specimens were obtained from 30 gastric and 49 colorectal cancer patients who underwent R0 resection followed by postoperative 5-FU based adjuvant chemotherapy. Immunohistochemical examinations of NF-κB and JNK on tissue microarrays (TMAs) revealed that significantly shorter time-to-relapse (TTR) in both NF-κB(+) and JNK(-) subgroups in both gastric (NF-κB(+), p = 0.0002, HR11.7. 95%CI3 3.2-43.4; JNK(-), p = 0.0302, HR4.4, 95%CI 1.2-16.6) and colon (NF-κB(+), p = 0.0038, HR36.9, 95%CI 3.2-426.0; JNK(-), p = 0.0098, HR3.2, 95%CI 1.3-7.7) cancers. These protein expression patterns also show strong discriminately power in gastric cancer patients for overall survival rate, suggesting a potential utility as prognostic or chemosensitivity markers. Baseline expression of these proteins using gastric cancer cell lines demonstrated the reciprocal patterns between NF-κB and JNK, while 5-FU exposure of these cell lines only induced NF-κB, suggesting that NF-κB plays a dominant role in the response to 5-FU. Subsequent siRNA experiments confirmed that gene knockdown of NF-κB increased 5-FU-specific sensitivity, whereas that of JNK did not affect the chemosensitivity. These results suggest that the expression of these proteins may aid in the decisions involved with adjuvant chemotherapy for gastrointestinal tract cancers.

Original languageEnglish
Article numbere43236
JournalPloS one
Issue number8
Publication statusPublished - 14-08-2012
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers'. Together they form a unique fingerprint.

Cite this